DRUG DIVERSION REGS "SPECIFIC TO" BULK PHARMACEUTICALS SHOULD BE ESTABLISHED
DRUG DIVERSION REGS "SPECIFIC TO" BULK PHARMACEUTICALS SHOULD BE ESTABLISHED if the Prescription Drug Marketing Act is to be applied to bulk pharmaceutical chemicals, the Generic Pharmaceutical Industry Association maintains in comments on FDA's proposed regulations implementing PDMA. "If BPCs are to be included in the proposed regulations, the proposed rule should be amended to include regulations specific to and appropriate to BPCs that address the problems of diversion and counterfeiting," GPIA said.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth